

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	1700.0610001/BJD/WBC
-------	---	----	---	------------------------	----------------------

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If Known)			
	AA				
	AB				
	AC				
	AD				
	AE3	US 6,054,312 B1	25-Apr-2000	Larocca et al.	
	AF3	US 6,159,728 B1	12-Dec-2000	Stockley et al.	
	AG3	US 6,207,646 B1	27-Mar-2001	Krieg et al.	
	AH3	US 6,239,116 B1	29-May-2001	Krieg et al.	
	AI3	US 6,429,199 B1	6-Aug-2002	Krieg et al.	
	AJ3	US 6,727,230 B1	27-Apr-2004	Hutcherson et al.	
	AK				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>4</sup> Kind Code <sup>5</sup> (in known)				
	AL					
	AM					
	AN					
	AO					
	AP9	EP 0 468 520 A2	29-Jan-1992	Mitsui Toatsu Chemicals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Rev. 11-03-03 svb

Substitute for form 1449A/PTO				<b>Complete If Known</b>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/550,580
(Use as many sheets as necessary)				<i>Filing Date</i>	September 23, 2005
				<i>First Named Inventor</i>	Bachmann, M.
				<i>Art Unit</i>	1648
				<i>Examiner Name</i>	Kinsey White, Nicole Erin
				<i>Attorney Docket Number</i>	1700.0610001/BJD/WBC
Sheet	2	of	2		

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If Known)			
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>4</sup> Kind Code <sup>5</sup> (in known)				
	AL10	WO 95/26204 A1	5-Oct-1995	Isis Pharmaceuticals, Inc.		
	AM10	WO 96/02555 A1	1-Feb-1996	The University of Iowa Research Foundation		
	AN10	WO 97/28259 A1	7-Aug-1997	The Reagents of the University of California		
	AO10	WO 99/11275 A2	11-Mar-1999	The Reagents of the University of California		
	AP					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete If Known
<i>Application Number</i>				10/550,580
<i>Filing Date</i>				September 23, 2005
<i>First Named Inventor</i>				BACHMANN, M.
<i>Art Unit</i>				1648
<i>Examiner Name</i>				Kinsey White, Nicole Erin
Sheet	1	of	2	Attorney Docket Number
				1700.0610001/BJD/WBC

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL87	Axblom, <i>et al.</i> , (1998) <i>Virology</i> 249(NA):80-8, Academic Press -- Structure of Phage fr Capsids with a Deletion in the FG loop: Implications for Viral Assembly	
	NPL88	Halpern, <i>et al.</i> , (1996) <i>Cell Immunol</i> 167(1):72-8, Academic Press -- Bacterial DNA induces murine interferon- $\gamma$ production by stimulation of interleukin-12 and tumor necrosis factor- $\alpha$ .	
	NPL89	Kline, <i>et al.</i> , (1996) <i>J. Invest Med</i> 44(7):380A, Lippincott Williams & Wilkins -- CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma	
	NPL90	Kline, <i>et al.</i> , (1998) <i>J Immunol</i> 160(6):2555-9, The American Association of Immunologists -- Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma.	
	NPL91	Kline, <i>et al.</i> , (2002) <i>Am J Physiol Lung Cell Mol Physiol</i> 283(1):L170-9, The American Physiological Society -- Treatment of established asthma in a murine model using CpG oligodeoxynucleotides.	
	NPL92	Klinman, <i>et al.</i> , (1996) <i>Proc Natl Acad Sci U S A</i> 93(7):2879-83, National Academy of Sciences -- CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.	
	NPL93	Krieg (1999) <i>Biochim Biophys Acta</i> 1489(1):107-16, Elsevier Science B.V. -- Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.	
	NPL94	Krieg (2002) <i>Annu Rev Immunol</i> 20:709-60, Annual Reviews -- CpG motifs in bacterial DNA and their immune effects.	
	NPL95	Krieg and Davis (2001) <i>Curr Opin Mol Ther</i> 3(1):15-24, Pharma Press Ltd -- Enhancing vaccines with immune stimulatory CpG DNA.	
	NPL96	Krieg, <i>et al.</i> , (1995) <i>Nature</i> 374(6522):546-9, Nature Publishing Group -- CpG motifs in bacterial DNA trigger direct B-cell activation.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	1700.0610001/BJD/WBC
-------	---	----	---	------------------------	----------------------

**Complete If Known**

Application Number	10/550,580
Filing Date	September 23, 2005
First Named Inventor	BACHMANN, M.
Art Unit	1648
Examiner Name	Kinsey White, Nicole Erin

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL97	Krieg, et al., (1996) Antisense Nucleic Acid Drug Dev 6(2):133-9, Mary Ann Liebert, Inc. -- Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs.	
	NPL98	Kuramoto, et al., (1992) Cancer Immunol Immunother 34(5):283-8, Springer-Verlag -- Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction.	
	NPL99	Lotz, et al., (1987) J Rheumatol 14(1):42-5, Journal Of Rheumatology Publishing Co. -- Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus.	
	NPL100	Peabody (1997) Arch Biochem Biophys 347(1):85-92, Academic Press -- Subunit fusion confers tolerance to peptide insertions in a virus coat protein.	
	NPL101	Raz, et al., (1996) Proc Natl Acad Sci U S A 93(10):5141-5, National Academy of Sciences -- Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.	
	NPL102	Stonehouse and Stockley (1993) FEBS Lett 334(3):355-9, Elsevier Science Publishers B.V. -- Effects of amino acid substitution on the thermal stability of MS2 capsids lacking genomic RNA.	
	NPL103	Weiner, et al., (1997) Proc Natl Acad Sci U S A 94(20):10833-7, National Academy of Sciences -- Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.	
	NPL104	Yamamoto, et al., (1992) Microbiol Immunol 36(9):983-97, Japanese Society For Bacteriology -- DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth.	
	NPL105	Yamamoto, et al., (1994) Jpn J Cancer Res 85(8):775-9, Japanese Cancer Association -- Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> .	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.